Advertisement

Pharmakologische Grundlage der ‚Therapieresistenz‘ bei der Behandlung mit Antidepressiva

  • A. Delini-Stula
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 5)

Zusammenfassung

Die Therapie-Resistenz auf die Behandlung mit Antidepressiva ist ein Problem, mit welchem praktizierende Ärzte in zunehmendem Maße konfrontiert sind. Immerhin sprechen ca. 30%-35% der depressiven Patienten ungenügend oder gar nicht auf eine pharmakologische Behandlung an.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Åsberg M, Bertilsson L (1979) Serotonin in depressive illness. In: Saletu B, Berner P, Hollister LE (Hrsg) Studies of CSF 5-HIAA in Neuropsychopharmacology. Pergamon Press, New York, pp 105–115Google Scholar
  2. Banki CM, Molnar G, Vojnik M (1981) Cerebrospinal fluid amine metabolites, tryptophane and clinical parameters in depression. J Affect Dis 3:91–99PubMedCrossRefGoogle Scholar
  3. Carlsson A et al. (1969) Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur J Pharmacol 5:357–366PubMedCrossRefGoogle Scholar
  4. Delini-Stula A (1983) Pharmakologie der Antidepressiva. In: Larger G, Heimann H (Hrsg) Psychopharmaka, Grundlagen und Therapie. Springer Verlag, Berlin Heidelberg New York Tokyo, pp 81–95Google Scholar
  5. Delini-Stula A (1987) Biochemische Klassifizierung der Antidepressiva und deren klinische Validierung. In: Simhandl Ch et al. (Hrsg) Moderne Psychiatrie, Klassifikationsprobleme in der Psychiatrie. MVP Verlag, Purkersdorf, pp 131–148Google Scholar
  6. Delini-Stula A, Schiwy W (1989) Verhütung von Panikattacken mit Imipramin und Clomipramin: Pharmakologische Begründung und Zusammenfassung der klinischen Befunde. In: Kielholz P, Adams P (Hrsg) Die Vielfalt von Angstzuständen. Deutscher Ärzte-Verlag, Köln, pp 177–187Google Scholar
  7. Eriksson EL (1987) Brain neurotransmitters in panic disorders. Acta Psych Scand [Suppl 335] 76:31–39CrossRefGoogle Scholar
  8. Flament MF et al. (1987) Biochemical changes during clomipramine treatment in childhood obsessive- compulsive disorder. Acta Gen Psychiatr 44 [3]:219–225CrossRefGoogle Scholar
  9. Healy D, Carney PA, Leonard BE (1982) Monoamine-related markers of depression: Changes following treatment. J Psych Res 17 [3]:251–260CrossRefGoogle Scholar
  10. Healy D, Carney PA, Leonard BE (1984) Biochemical correlates of antidepressant response. Results of a trazodone versus amitriptyline trial. Psychopathology 17 [Suppl 2]:82–87PubMedCrossRefGoogle Scholar
  11. Lapin IP, Oxenkrug GF (1969) Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1:132–136PubMedCrossRefGoogle Scholar
  12. Lecrubier Y, Puech AJ, Boyer P (1990) The contribution of neuropharmacology to the understanding of ill-defined psychological disorders. In: Sartorius N et al. (eds) Psychological disorders in general medical settings. Hogrefe & Huber Publ, Toronto Lewiston New York Bern Stuttgart, pp 98–110Google Scholar
  13. Maas JW et al. (1982) Pre-treatment neurotransmitter metabolites in response to imipramine and amitriptyline treatment. Psych Med 12:37–43CrossRefGoogle Scholar
  14. Maas JW et al. (1984) Pre-treatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs. Am J Psychiatr 141:1159–1171PubMedGoogle Scholar
  15. Maitre L et al. (1980) Amine uptake inhibitors: Criteria of selectivity. In: Svensson TH, Carlsson A (eds) Biogenic amines and affective disorders. Acta Psych Scand 61 [Suppl 280]: p 97–110Google Scholar
  16. Maitre L et al. (1982) 5-HT uptake inhibitors: Psychopharmacological and biochemical criteria of selectivity. In: Ho BT, Schoolar JC, Usdin E (eds) Advances in biochemical psychopharmacology. Serotonin in biological psychiatry. Raven Press, New York, pp 229–246Google Scholar
  17. Mouret J, Lemoine P, Minuit M-P (1987) Marquers polygraphiques, cliniques et thérapeutiques des dépressions dopamine-dépendantes (DDD). CR Acad Sci, Vol 305, series III:301–306Google Scholar
  18. Randrup A et al. (1975) Mania, depression and brain dopamine. In: Essmann WB, Valzelli L (eds) Current developments in psychopharmacology, vol 2. Spectrum Publ, New York, pp 205–248Google Scholar
  19. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatr 122:509–522PubMedGoogle Scholar
  20. Timmerman L et al. (1987) A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharm 2:239–253CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Delini-Stula

There are no affiliations available

Personalised recommendations